Merck & Co (MRK) Stock Price

Currency:

Merck & Co Price

🇺🇸NYSE·CLOSED

115.91USD

Market closed

Today +/-

-0.73 USD

Today %

-0.63 %

Merck & Co (MRK) — ISIN US58933Y1055. The Merck & Co stock price was 115.91 USD in 2026. Revenue was 67.39 B USD. Earnings were 13.56 B USD. P/E ratio was 21.42. Merck & Co operates in the Health sector.

Merck & Co stock price

Ex-Dividend

Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Merck & Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Merck & Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Merck & Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Merck & Co Stock Price History

Date	Merck & Co Price
3/13/2026	115.91 USD
3/12/2026	115.56 USD
3/11/2026	115.79 USD
3/10/2026	117.88 USD
3/6/2026	115.59 USD
3/5/2026	116.25 USD
2/27/2026	119.42 USD
2/26/2026	119.38 USD
2/25/2026	122.55 USD
2/23/2026	123.54 USD
2/20/2026	122.35 USD
2/19/2026	122.02 USD
2/17/2026	121.66 USD
2/16/2026	121.57 USD
2/12/2026	121.41 USD

API Docs Get API Key

Merck & Co Revenue, EBIT, Net Income

3 Years
5 Years
10 Years
25 Years
Max

Unlock the full history with 30+ years of data and forecast estimates.

Unlock all data — PRO

Revenue

EBIT

Net Income

Details

API Docs Get API Key

Merck & Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Mar 14, 2026, 3:12 PM

REVENUE (B USD)

REVENUE GROWTH (%)

GROSS MARGIN (%)

GROSS INCOME (B USD)

NET INCOME (B USD)

NET INCOME GROWTH (%)

DIVIDEND (USD)DIV. (USD)

DIVIDEND GROWTH (%)DIV. GROWTH (%)

SHARES (B)

DOCUMENTS

1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e	2027e	2028e	2029e	2030e	2031e
3.25	3.56	3.55	4.13	5.06	5.94	6.55	7.67	8.6	9.66	10.5	14.97	16.68	19.83	23.64	26.9	32.71	40.36	21.2	21.45	22.49	22.97	22.01	22.64	24.2	23.85	27.43	45.99	48.05	47.27	44.03	42.24	39.5	39.81	40.12	42.29	39.12	41.52	48.7	59.28	60.12	64.17	65.01	67.39	70.94	75.52	75.13	74	74.09
–	9.64	-0.34	16.38	22.60	17.35	10.29	17.11	12.14	12.32	8.65	42.59	11.44	18.87	19.21	13.80	21.62	23.38	-47.48	1.16	4.85	2.17	-4.18	2.84	6.90	-1.43	15.00	67.66	4.48	-1.62	-6.84	-4.08	-6.48	0.78	0.79	5.41	-7.50	6.13	17.31	21.72	1.40	6.74	1.31	3.66	5.28	6.45	-0.52	-1.51	0.12
61.06	59.99	64.14	67.59	71.47	74.31	76.34	76.82	77.51	78.31	76.20	60.17	55.30	53.00	50.12	48.23	46.40	44.39	82.90	81.32	80.27	78.39	76.61	73.48	74.62	76.59	67.12	60.00	64.89	65.21	63.61	64.05	63.22	66.08	68.50	69.11	71.73	72.10	72.81	70.98	73.53	77.09	81.50	78.63	74.68	70.16	70.52	71.60	71.52
1.98	2.14	2.28	2.79	3.62	4.41	5	5.89	6.67	7.57	8	9.01	9.22	10.51	11.85	12.97	15.18	17.92	17.57	17.44	18.05	18.01	16.86	16.63	18.06	18.27	18.41	27.59	31.18	30.82	28.01	27.05	24.97	26.31	27.48	29.23	28.06	29.94	35.46	42.08	44.2	49.47	52.98	52.98	52.98	52.98	52.98	52.98	52.98
0.45	0.49	0.54	0.68	0.91	1.21	1.5	1.78	2.12	1.98	2.17	3	3.34	3.88	4.61	5.25	5.89	6.82	7.28	7.15	6.83	5.83	4.63	4.43	3.27	7.79	12.85	0.86	6.26	6.17	4.4	11.92	4.44	3.92	2.39	6.22	9.84	7.07	13.05	14.52	0.37	17.12	18.25	13.56	25.07	27.14	25.94	24.95	25
–	9.56	9.33	25.23	34.22	33.11	23.96	19.13	19.09	-6.46	9.17	38.37	11.28	16.37	18.89	13.74	12.23	15.81	6.74	-1.81	-4.46	-14.64	-20.57	-4.28	-26.33	138.46	65.04	-93.32	628.41	-1.47	-28.56	170.66	-62.73	-11.75	-38.93	159.82	58.25	-28.20	84.65	11.27	-97.49	4,589.59	6.64	-25.69	84.85	8.25	-4.41	-3.83	0.22
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.52	1.52	1.52	1.52	1.52	1.56	1.69	1.73	1.77	1.81	1.85	1.89	1.99	2.26	2.48	2.64	2.80	2.96	3.12	3.28	3.40	5.60	6.11	-	-	-
–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.63	8.33	2.37	2.31	2.26	2.21	2.16	5.29	13.57	9.73	6.45	6.06	5.71	5.41	5.13	3.66	64.71	9.11	–	–	–
2.66	2.64	2.57	2.55	2.48	2.4	2.4	2.37	2.36	2.31	2.31	2.55	2.54	2.49	2.47	2.44	2.4	2.35	2.32	2.28	2.25	2.23	2.2	2.19	2.19	2.14	2.27	3.12	3.09	3.08	3	2.93	2.84	2.79	2.75	2.68	2.58	2.54	2.54	2.54	2.55	2.54	2.51	2.51	2.51	2.51	2.51	2.51	2.51
–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Merck & Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Merck & Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Merck & Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Merck & Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Merck & Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

ASSETS

CASH BALANCE (B USD)

RECEIVABLES (B USD)

OTHER RECEIVABLES (M USD)OTHER REC. (M USD)

INVENTORIES (B USD)

OTHER CURRENT ASSETS (B USD)OTHER CURRENT LIAB. (B USD)

CURRENT ASSETS (B USD)

TANGIBLE ASSETS (B USD)

LONG-TERM INVESTMENTS (B USD)LONG-T. INVEST. (B USD)

LONG-TERM RECEIVABLES (M USD)LONG-T. REC. (M USD)

INTANGIBLE ASSETS (B USD)INTANGIBLE ASSETS (B USD)

GOODWILL (B USD)

OTHER NON-CURRENT ASSETS (B USD)OTHER NON-CURRENT ASSETS (B USD)

NON-CURRENT ASSETS (B USD)

TOTAL ASSETS (B USD)

LIABILITIES

COMMON STOCK (B USD)

ADDITIONAL PAID-IN CAPITAL (B USD)

RETAINED EARNINGS (B USD)

OTHER EQUITY (M USD)OTHER EQUITY (M USD)

UNREALIZED GAINS/LOSSES (M USD)UNREAL. GAINS/LOSSES (M USD)

EQUITY (B USD)

LIABILITIES (B USD)

PROVISIONS (B USD)

OTHER SHORT-TERM LIABILITIES (B USD)OTHER SHORT-TERM LIAB. (B USD)

SHORT-TERM DEBTS (M USD)SHORT-TERM DEBTS (M USD)

SHORT-TERM PORTION OF LONG-TERM DEBTS (B USD)LONG-TERM DEBT PORTION (B USD)

SHORT-TERM RECEIVABLES (B USD)SHORT-TERM REC. (B USD)

LONG-TERM LIABILITIES (B USD)LONG-T. LIAB. (B USD)

DEFERRED TAXES (B USD)

OTHER LIABILITIES (B USD)OTHER LIAB. (B USD)

LONG-TERM LIABILITIES (B USD)LONG-T. LIABILITIES (B USD)

DEBT (B USD)

TOTAL CAPITAL (B USD)

1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024

0.37	0.74	0.84	0.97	1.15	1.55	1.14	1.2	1.41	1.09	1.54	2.27	3.35	2.18	2.31	3.36	3.2	4.25	3.29	4.97	4.17	7.09	15.64	8.71	8.23	5.49	9.6	12.2	14.97	16.14	17.49	15.72	13.43	14.34	8.5	8.86	10.45	8.06	8.1	13.19	7.09	13.69
0.71	0.81	0.86	0.91	1.08	1.02	1.27	1.35	1.55	1.74	2.09	2.35	2.5	2.66	2.88	3.37	4.09	5.26	5.22	5.42	4.02	3.63	2.93	3.31	3.37	3.53	6.94	7.69	8.54	7.97	7.18	6.63	6.48	7.02	6.87	7.07	6.78	7.85	9.23	9.45	10.35	10.28
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	906	0	0	0	0	0	0	0	0	0	0	0	0	0	0	660	723	841
0.57	0.57	0.54	0.58	0.66	0.66	0.78	0.89	0.99	1.18	1.64	1.66	1.87	2.15	2.15	2.62	2.85	3.02	3.58	2.96	2.55	1.9	1.66	1.77	1.88	2.09	8.05	5.87	6.25	6.54	6.23	5.57	4.7	4.87	5.1	5.44	5.98	6.31	5.95	5.91	6.36	6.11
0.09	0.06	0.06	0.06	0.12	0.16	0.22	0.33	0.36	0.39	0.46	0.64	0.9	0.74	0.88	0.87	1.12	1.06	0.88	1.03	0.78	0.86	0.83	1.43	0.66	8	3.84	3.3	3.42	4.21	4.79	4.69	5.14	4.39	4.3	4.5	4.28	5.54	6.99	6.51	7.65	7.87
1.73	2.18	2.31	2.51	3.01	3.39	3.41	3.77	4.31	4.4	5.73	6.92	8.62	7.73	8.21	10.23	11.26	13.6	12.96	14.39	11.53	13.48	21.05	15.23	15.05	19.11	28.43	29.06	33.18	34.86	35.69	32.61	29.75	30.61	24.77	25.88	27.48	27.76	30.27	35.72	32.17	38.78
1.72	1.91	1.88	1.91	1.95	2.07	2.29	2.72	3.5	4.27	4.89	5.3	5.27	5.93	6.61	7.84	9.68	11.48	13.1	14.2	14.17	14.71	14.4	13.19	12.35	12	18.28	17.08	16.3	16.03	14.97	13.14	12.51	12.03	12.44	13.29	16.13	17.99	19.28	22.77	24.49	25.15
0.09	0.18	0.4	0.39	0.46	0.4	0.74	1.01	1.04	1.42	1.78	1.42	1.97	2.5	2.53	3.61	4.76	4.95	6.98	7.26	7.94	6.73	4.11	11.29	11.06	7.89	1.31	2.67	4.34	8.61	11.37	13.85	13.06	12.13	12.89	6.23	1.89	1.37	0.97	2.45	1.5	1.59
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3.36	3.11	0.86	0.68	0.52	0.94	0.71	0.53	47.76	39.46	34.3	29.08	23.8	20.39	22.6	17.31	14.18	11.43	14.2	14.6	22.93	20.27	18.01	16.37
0	0	0	0	0	0	0	0	0	0.15	6.65	7.21	6.83	6.74	6.78	8.29	7.58	7.37	4.13	4.13	1.09	1.09	1.09	1.43	1.45	1.44	12.04	12.38	12.16	12.13	12.3	12.99	17.72	18.16	18.28	18.25	19.43	20.24	21.26	21.2	21.2	21.67
0.67	0.32	0.31	0.3	0.27	0.27	0.32	0.53	0.64	0.85	0.87	1.01	1.15	1.4	1.6	1.89	2.35	2.75	3.48	4.48	5	5.89	3.69	2.48	7.73	6.23	4.5	5.13	4.85	5.42	7.52	5.2	6.04	5.14	5.31	7.55	5.28	9.63	10.99	6.75	9.31	13.54
2.48	2.41	2.59	2.59	2.67	2.74	3.35	4.26	5.19	6.69	14.19	14.93	15.21	16.57	17.52	21.62	24.38	26.56	31.06	33.18	29.06	29.1	23.8	29.34	33.31	28.08	83.88	76.72	71.95	71.28	69.96	65.56	71.93	64.76	63.11	56.76	56.91	63.82	75.43	73.44	74.51	78.32
4.21	4.59	4.9	5.11	5.68	6.13	6.76	8.03	9.5	11.09	19.93	21.86	23.83	24.29	25.74	31.85	35.63	40.15	44.02	47.56	40.59	42.57	44.85	44.57	48.35	47.2	112.31	105.78	105.13	106.13	105.65	98.17	101.68	95.38	87.87	82.64	84.4	91.59	105.69	109.16	106.68	117.11

0	0	0	0	0.15	0.15	0.15	0.17	0.19	0.2	4.58	4.67	4.74	4.97	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	1.78	1.79	1.79	1.79	1.79	1.79	1.79	1.79	1.79	1.79	1.79	1.79	1.79	1.79	1.79	1.79
0.15	0.15	0.15	0.15	0	0	0	0	0	0	0	0	0	0	5.22	5.61	5.92	6.27	6.91	6.94	6.96	6.87	6.9	7.17	8.01	8.32	39.68	40.7	40.66	40.65	40.51	40.42	40.22	39.94	39.9	38.81	39.66	39.59	44.24	44.38	44.51	44.7
2.41	2.68	2.98	3.38	3.92	4.58	5.39	6.39	7.59	8.47	9.39	10.94	12.74	14.82	17.29	20.19	23.45	27.36	31.49	35.44	34.14	36.63	37.98	39.1	39.14	43.7	41.41	37.54	38.99	39.99	39.26	46.02	45.35	44.13	41.35	42.58	46.6	47.36	53.7	61.08	53.9	63.07
24.7	26	26.3	0	0	0	0	0	0	0	0	0	0	0	9	-21.3	8.1	30.8	10.6	-99	65.5	-45.9	52.3	-1,164.3	-826.1	-2,553.9	-2,800	-3,247	-3,153	-4,755	-2,251	-4,434	-4,189	-5,223	-4,849	-5,467	-6,211	-6,634	-4,429	-4,768	-5,161	-4,945
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	33	31	21	73	54	111	41	-3	-61	-78	18	0	0	0	0	0
2.59	2.86	3.16	3.53	4.07	4.73	5.55	6.55	7.77	8.67	13.97	15.61	17.48	19.79	22.55	25.81	29.41	33.69	38.44	42.31	41.19	43.48	44.96	45.13	46.36	49.49	80.1	76.81	78.31	77.74	79.36	83.91	83.21	80.63	78.13	77.63	81.86	82.1	95.29	102.48	95.03	104.62
0.51	0.59	0.68	0.77	0.91	0.83	0.94	1.14	1.4	1.46	2.38	2.72	3.11	2.94	3.27	3.68	4.16	4.61	1.9	2.41	0.74	0.42	0.47	0.5	0.62	0.62	2.24	2.31	2.02	1.75	2.27	2.63	2.53	2.81	3.1	3.32	3.74	4.59	4.61	4.26	3.92	4.08
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3.21	3.37	3.77	5.29	5.28	6.65	8.53	9.17	9.46	8.51	10.17	9.74	9.34	10.44	11.18	10.17	10.26	10.07	12.45	13.05	13.86	13.61	15.19	14.83
0.12	0.1	0.2	0.27	0.45	0.62	0.64	0.9	1.08	1.33	1.78	2.59	1.22	1.29	1.4	1.76	1.74	2.03	2.37	2.93	3.36	3.85	4.52	4.29	1.28	2.23	2.36	2.42	2.06	2.54	1.73	2.63	2.91	3.66	2.19	3.51	2.42	3.25	2.99	4.42	5.21	6.86
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	207	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0.37	0.41	0.33	0.37	0.85	0.46	0.33	0.79	0.34	0.83	1.74	0.15	0.42	0.61	0.9	0.62	2.86	3.32	4.07	3.67	1.7	2.18	2.97	1.29	1.82	2.3	1.38	2.4	1.99	4.32	4.52	2.7	2.58	0.57	3.06	5.31	3.61	6.43	2.41	1.95	1.37	2.65
1	1.1	1.2	1.42	2.21	1.91	1.91	2.83	2.81	3.62	5.9	5.45	4.75	4.83	5.57	6.07	8.76	9.95	11.54	12.38	9.57	11.74	13.24	12.72	12.26	14.32	15.64	15.64	16.25	18.35	17.87	18.4	19.2	17.2	18.61	22.21	22.22	27.33	23.87	24.24	25.69	28.42
0.39	0.18	0.17	0.17	0.17	0.14	0.12	0.12	0.49	0.5	1.12	1.15	1.37	1.16	1.35	3.22	3.14	3.6	4.8	4.88	5.1	4.69	5.13	5.55	3.92	3.94	16.1	15.48	15.53	16.25	20.54	18.7	23.83	24.27	21.35	19.81	22.74	25.36	30.69	28.75	33.68	34.46
0.37	0.48	0.57	0.57	0	0	0	0	0	1.34	1.74	2.91	3.69	4.03	5.06	6.06	7.03	6.75	6.79	7.18	6.43	6.44	6.09	6.33	11.59	7.77	19.09	17.85	16.42	16.07	6.78	4.47	6.54	5.08	2.22	1.7	1.47	1.02	3.44	1.8	0.87	1.39
0	0	0	0	1.19	1.22	1.21	1.24	1.27	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8.14	7.81	7.35	8.51	11.12	12.04	11.97	12.48	9.43	8.32	8.79	6.47
0.76	0.66	0.74	0.74	1.35	1.36	1.33	1.37	1.77	1.84	2.87	4.06	5.06	5.18	6.41	9.28	10.17	10.35	11.59	12.06	11.53	11.13	11.22	11.88	15.5	11.71	35.19	33.34	31.94	32.32	35.45	30.98	37.71	37.87	34.69	33.55	36.18	38.86	43.57	38.86	43.35	42.31
1.76	1.76	1.95	2.15	3.56	3.27	3.24	4.2	4.58	5.46	8.76	9.51	9.81	10.01	11.98	15.35	18.93	20.3	23.13	24.43	21.1	22.88	24.46	24.6	27.76	26.03	50.83	48.98	48.19	50.67	53.32	49.38	56.91	55.07	53.3	55.76	58.4	66.18	67.44	63.1	69.04	70.73
4.35	4.62	5.11	5.69	7.63	8	8.78	10.75	12.36	14.13	22.73	25.12	27.29	29.8	34.53	41.16	48.34	53.99	61.57	66.74	62.29	66.36	69.42	69.73	74.12	75.52	130.93	125.79	126.49	128.41	132.68	133.29	140.12	135.7	131.43	133.39	140.25	148.29	162.73	165.58	164.07	175.35

Details

Balance Sheet

ⓘ

What Is the Balance Sheet?

The balance sheet is a financial snapshot of Merck & Co at a specific point in time. It follows the fundamental equation: Assets = Liabilities + Shareholders' Equity. Unlike the income statement (which covers a period), the balance sheet tells you what the company owns, what it owes, and what belongs to shareholders at a given date.

Assets

Current assets (cash, receivables, inventory) can be converted to cash within 12 months and indicate short-term liquidity. Non-current assets (property, equipment, intangible assets, goodwill) represent long-term investments. A high proportion of cash and short-term investments gives Merck & Co financial flexibility to weather downturns, fund acquisitions, or return capital to shareholders.

Liabilities

Current liabilities (accounts payable, short-term debt) are obligations due within one year. Non-current liabilities (long-term debt, pension obligations) are due further out. Key ratio to watch: the debt-to-equity ratio (Total Debt ÷ Shareholders' Equity). A ratio below 1.0 is generally healthy, meaning the company is funded more by equity than debt. Highly leveraged companies amplify both gains and losses.

Shareholders' Equity

Equity is the residual value belonging to shareholders after all debts are paid. It includes retained earnings (accumulated profits not paid out as dividends) and paid-in capital. Rising equity year over year is a positive sign — it means Merck & Co is building book value. Declining equity, especially when driven by losses or heavy share buybacks funded by debt, warrants closer scrutiny.

Key Ratios to Derive

From the balance sheet, you can calculate the current ratio (current assets ÷ current liabilities; above 1.5 is comfortable), book value per share (equity ÷ shares outstanding), and return on equity (net income ÷ equity; above 15 % is strong). Tracking these ratios over time reveals whether Merck & Co is strengthening or weakening its financial position.

NET INCOME (B USD)

DEPRECIATION AND AMORTIZATION B USDDEPRECIATION (B USD)

DEFERRED TAXES (B USD)

CHANGES IN WORKING CAPITAL (B USD)CHANGES IN WORKING CAPITAL (B USD)

NON-CASH ITEM (B USD)

PAID INTEREST (B USD)

PAID TAXES (B USD)

Net Cash Flow from Operating Activities (B USD)NET CASH FLOW FROM OPERATING ACTIVITIES (B USD)

CAPITAL EXPENDITURES (M USD)

CASH FLOW FROM INVESTING ACTIVITIES (B USD)CASH FLOW FROM INVESTING ACTIVITIES (B USD)

CASH FLOW FROM OTHER INVESTING ACTIVITIES (B USD)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B USD)

INTEREST INCOME AND EXPENSES (M USD)

NET DEBT CHANGE (B USD)NET DEBT CHANGE (B USD)

Net change in equity (M USD)NET CHANGE IN EQUITY (M USD)

CASH FLOW FROM FINANCING ACTIVITIES (B USD)CASH FLOW FROM FINANCING ACTIVITIES (B USD)

OTHER ITEMS OF FINANCING CASH FLOWS (B USD)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B USD)

TOTAL DIVIDENDS PAID (M USD)

NET CHANGE IN CASH FLOW (B USD)

FREE CASH FLOW (M USD)

SHARE-BASED COMPENSATION (M USD)

1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
0.68	0.91	1.21	1.5	1.78	2.12	1.98	3.1	4.42	4.8	5.54	6.46	8.13	8.62	6.82	7.28	7.15	6.83	5.83	4.63	4.43	3.4	7.93	13.02	0.98	6.39	6.3	4.52	11.93	4.46	3.94	2.42	6.19	9.78	4.52	12.36	14.53	0.38	17.13
0.19	0.21	0.2	0.22	0.25	0.25	0.3	0.39	0.68	0.67	0.73	0.84	1.02	1.14	1.27	1.13	1.23	1.31	1.45	1.71	2.27	1.99	1.63	2.58	7.38	7.43	6.98	6.99	6.69	6.38	5.44	4.64	4.52	3.65	3.49	3.21	3.91	3.87	4.5
0.04	-0.07	-0.14	-0.07	-0.13	0	-0.02	0	0	0	0	0	0	0	-0.09	0.46	0.39	0.13	0.05	0.01	-0.53	-1.78	0.53	1.82	-1.09	-1.54	0.67	-0.33	-2.6	-0.76	-1.52	-2.62	-0.51	-0.56	-0.57	0.19	-1.57	-1.9	-1.25
0.14	0.12	0.22	-0.27	0.23	0.06	-0.17	-1.15	-0.95	-2.5	-1.02	-1.3	-2.87	-3.14	-0.4	0.05	0.41	0.49	1.5	1.18	-0.14	1.36	-3.98	-2.71	0.93	-0.77	-4.14	-0.79	1.82	-0.27	-2.6	-5.02	-1.55	-2.07	-4.6	-3.84	-2.78	-2.21	-3.67
-0.03	-0.02	-0.1	0	-0.08	-0	0.41	0.71	-0	-0.02	0.18	0.32	-0.95	-0.5	0.09	-0.26	0.1	1.13	-0.04	0.08	1.04	2.37	0.81	-10.91	3.13	1.24	0.55	1.55	-9.71	2.92	5.42	7.35	2.62	3.02	7.85	2.67	5.55	13.51	5.51
0	0.05	0.08	0.06	0.06	0.07	0.06	0.09	0.14	0.09	0.12	0.13	0.19	0.28	0.45	0.47	0.4	0.36	0.28	0.35	0.39	0.41	0.25	0.35	0.76	0.6	0.9	0.92	0.85	0.65	0.69	0.72	0.78	0.84	0.82	0.78	0.94	1.1	1.3
0.27	0.43	0.62	0.83	0.83	0.88	0.93	0.86	0.86	2	1.1	1.3	2.1	2.48	2.17	2.1	1.8	2	1.9	1.7	2.4	3.5	1.8	0.96	1.6	2.7	2.5	2.3	7.9	1.8	1.8	4.9	1.5	4.5	2.7	2.4	3.2	4.34	3.93
1.02	1.15	1.39	1.38	2.06	2.43	2.5	3.05	4.14	2.94	5.43	6.32	5.33	6.13	7.69	8.66	9.29	9.89	8.8	7.61	6.77	7	6.57	3.39	10.82	12.38	10.02	11.65	7.86	12.42	10.38	6.45	10.92	13.44	10.25	14.11	19.1	13.01	21.47
-210	-253	-372	-433	-670	-1,041	-1,066	-1,012	-1,009	-1,005	-1,196	-1,448	-1,973	-2,560	-2,727	-2,401	-2,128	-1,915	-1,726	-1,402	-980	-1,011	-1,298	-1,460	-1,678	-1,723	-1,954	-1,548	-1,317	-1,283	-1,614	-1,888	-2,615	-3,473	-4,429	-4,448	-4,388	-3,863	-3,372
-0.3	-0.33	-0.11	-0.56	-1	-1.3	-1.35	-2.59	-0.03	-1.32	-1.98	-1.6	-0.01	-2.82	-3.64	-3.9	-3.77	-4.26	-1.64	2.27	-4.88	-2.81	-1.83	3.16	-3.5	-2.89	-6.81	-3.15	-0.37	-4.76	-3.21	2.68	4.31	-2.63	-9.44	-16.56	-4.96	-14.08	-7.73
-0.09	-0.08	0.27	-0.13	-0.33	-0.26	-0.29	-1.58	0.98	-0.32	-0.78	-0.15	1.96	-0.26	-0.91	-1.49	-1.64	-2.35	0.09	3.67	-3.9	-1.8	-0.54	4.62	-1.82	-1.17	-4.85	-1.6	0.94	-3.48	-1.6	4.57	6.93	0.84	-5.01	-12.11	-0.57	-10.22	-4.36
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0.03	0.46	-0.39	-0.15	0.48	-0.12	0.5	1.23	-1.4	0.48	-0.02	0.49	1.58	2.13	0.9	1.94	-0.39	-1.78	0.12	1.28	-1.27	-1.18	0.47	1.78	0.75	-0.47	3.16	4.53	-3.93	3.49	-1.31	-1.13	0.84	1.25	5.01	1.63	-2.25	4.18	2.31
-474	-979	29	-172	-707	-135	-810	-287	-565	-287	-2,051	-3,159	-3,135	-3,259	-1,404	-3,590	-1,773	-1,645	-2,234	-878	-632	-531	-2,622	186	-1,230	-1,600	-1,281	-5,306	-6,143	-3,701	-2,495	-3,515	-8,500	-4,419	-1,192	-638	384	-1,221	-1,129
-0.71	-0.84	-0.83	-0.96	-0.95	-1.14	-1.36	-0.21	-3.4	-1.4	-3.84	-4.86	-3.92	-3.87	-3.45	-5.07	-5.53	-6.83	-5.59	-3.04	-5.6	-4.87	-5.52	-1.64	-5.44	-6.9	-3.27	-5.99	-15.11	-5.27	-9.04	-10.01	-13.16	-8.86	-2.83	2.59	-9.12	-4.81	-7.03
0	0.01	0.03	0.02	0.03	0.02	0.02	0.02	-0.01	-0.06	-0.04	-0.15	-0.11	-0.15	-0.15	-0.28	-0.17	-0.15	-0.16	-0.09	-0.38	0.16	-0.09	-0.39	-0.23	-0.14	-0.03	-0.06	0.13	0.06	-0.12	-0.2	-0.33	0.01	-0.44	8.21	-0.24	-0.33	-0.37
-266	-334	-504	-650	-749	-893	-1,064	-1,174	-1,434	-1,539	-1,728	-2,039	-2,253	-2,589	-2,798	-3,145	-3,191	-3,250	-3,310	-3,349	-3,322	-3,307	-3,278	-3,215	-4,734	-4,691	-5,116	-5,157	-5,170	-5,117	-5,124	-5,167	-5,172	-5,695	-6,215	-6,610	-7,012	-7,445	-7,840
0.04	0.03	0.45	-0.17	0.12	-0.01	-0.22	0.25	0.77	0.24	-0.5	-0.23	1.48	-0.58	0.51	-0.39	0.1	-1.04	1.68	6.71	-3.67	-0.58	-0.97	4.94	1.59	2.63	-0.08	2.17	-8.18	1.08	-2.01	-0.42	1.87	1.97	-1.77	0.01	4.61	-5.86	6.41
811.6	894	1,014.1	947.7	1,384.8	1,392.5	1,437.8	2,035.8	3,130.6	1,938.7	4,231	4,867.8	3,354.9	3,570.2	4,959.5	6,262.1	7,157.6	7,977.7	7,073	6,205.8	5,785	5,988.2	5,273.4	1,931.4	9,144	10,660	8,068	10,106	6,543	11,138	8,762	4,559	8,307	9,967	5,824	9,661	14,707	9,143	18,096
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

API Docs Get API Key

Merck & Co Stock Quarterly Figures

REVENUE (B USD)

REVENUE GROWTH (%)

GROSS MARGIN (%)

GROSS INCOME (B USD)

NET INCOME (B USD)

NET INCOME GROWTH (%)

DIVIDEND (USD)DIV. (USD)

DIVIDEND GROWTH (%)DIV. GROWTH (%)

SHARES (B)

1990 Q1	1990 Q2	1990 Q3	1990 Q4	1991 Q1	1991 Q2	1991 Q3	1991 Q4	1992 Q1	1992 Q2	1992 Q3	1992 Q4	1993 Q1	1993 Q2	1993 Q3	1993 Q4	1994 Q1	1994 Q2	1994 Q3	1994 Q4	1995 Q1	1995 Q2	1995 Q3	1995 Q4	1996 Q1	1996 Q2	1996 Q3	1996 Q4	1997 Q1	1997 Q2	1997 Q3	1997 Q4	1998 Q1	1998 Q2	1998 Q3	1998 Q4	1999 Q1	1999 Q2	1999 Q3	1999 Q4	2000 Q1	2000 Q2	2000 Q3	2000 Q4	2001 Q1	2001 Q2	2001 Q3	2001 Q4	2002 Q1	2002 Q2	2002 Q3	2002 Q4	2003 Q1	2003 Q2	2003 Q3	2003 Q4	2004 Q1	2004 Q2	2004 Q3	2004 Q4	2005 Q1	2005 Q2	2005 Q3	2005 Q4	2006 Q1	2006 Q2	2006 Q3	2006 Q4	2007 Q1	2007 Q2	2007 Q3	2007 Q4	2008 Q1	2008 Q2	2008 Q3	2008 Q4	2009 Q1	2009 Q2	2009 Q3	2009 Q4	2010 Q1	2010 Q2	2010 Q3	2010 Q4	2011 Q1	2011 Q2	2011 Q3	2011 Q4	2012 Q1	2012 Q2	2012 Q3	2012 Q4	2013 Q1	2013 Q2	2013 Q3	2013 Q4	2014 Q1	2014 Q2	2014 Q3	2014 Q4	2015 Q1	2015 Q2	2015 Q3	2015 Q4	2016 Q1	2016 Q2	2016 Q3	2016 Q4	2017 Q1	2017 Q2	2017 Q3	2017 Q4	2018 Q1	2018 Q2	2018 Q3	2018 Q4	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1e	2026 Q2e	2026 Q3e	2026 Q4e
1.76	1.9	1.91	2.1	2.05	2.12	2.12	2.31	2.22	2.37	2.46	2.6	2.38	2.57	2.54	3	3.51	3.79	3.79	3.87	3.82	4.14	4.17	4.56	4.53	4.91	4.98	5.41	5.57	5.91	5.93	6.23	6.06	6.47	6.84	7.53	7.54	8.02	8.2	8.96	8.85	9.48	10.57	11.47	11.35	11.89	11.92	12.56	12.17	-2.21	5.43	6.06	5.57	5.53	5.76	5.63	5.63	6.02	5.54	5.75	5.36	5.47	5.42	5.77	5.41	5.77	5.41	6.04	5.77	6.11	6.07	6.24	5.82	6.05	5.94	6.03	5.39	5.9	6.05	10.09	11.42	11.35	11.13	12.09	11.58	12.15	12.02	12.29	11.73	12.31	11.49	11.74	10.67	11.01	11.03	11.32	10.26	10.93	10.56	10.48	9.43	9.79	10.07	10.22	9.31	9.84	10.54	10.12	9.43	9.93	10.33	10.43	10.04	10.47	10.79	11	10.82	11.76	12.4	4.15	10.29	9.35	10.93	10.95	10.63	11.4	13.15	13.52	15.9	14.59	14.96	13.83	14.49	15.04	15.96	14.63	15.78	16.11	16.66	15.62	15.53	15.81	17.28	16.4	16.09	16.73	17.97	17.23
–	8.02	0.79	9.72	-2.43	3.56	-0.24	9.31	-3.93	6.79	3.79	5.56	-8.54	8.15	-1.13	17.96	17.09	7.91	–	2.08	-1.39	8.36	0.85	9.25	-0.59	8.37	1.51	8.49	2.98	6.14	0.32	5.13	-2.79	6.80	5.69	10.13	0.08	6.38	2.22	9.36	-1.25	7.07	11.51	8.51	-1.06	4.83	0.22	5.35	-3.09	-118.14	-345.85	11.63	-8.02	-0.83	4.29	-2.34	0.05	6.94	-8.02	3.79	-6.72	1.96	-0.93	6.46	-6.19	6.69	-6.26	11.72	-4.55	5.93	-0.61	2.77	-6.73	3.93	-1.78	1.50	-10.73	9.55	2.54	66.85	13.17	-0.67	-1.95	8.71	-4.24	4.92	-1.06	2.26	-4.59	4.95	-6.69	2.18	-9.09	3.18	0.20	2.61	-9.33	6.53	-3.45	-0.71	-10.08	3.82	2.94	1.41	-8.84	5.71	7.03	-4.00	-6.73	5.26	3.98	1.05	-3.80	4.26	3.14	1.89	-1.65	8.73	5.42	-66.54	148.02	-9.09	16.85	0.17	-2.93	7.29	15.37	2.79	17.60	-8.23	2.51	-7.55	4.75	3.78	6.17	-8.34	7.83	2.14	3.38	-6.20	-0.61	1.78	9.30	-5.07	-1.87	3.94	7.41	-4.11
76.79	76.83	76.85	76.86	77.50	77.76	77.04	77.74	78.86	77.59	78.90	77.93	77.43	77.34	78.85	72.04	58.59	59.68	61.71	60.58	54.78	57.79	55.45	53.35	50.71	53.47	53.28	54.24	49.96	50.18	49.54	50.75	46.60	47.71	48.17	50.03	44.89	45.50	46.73	48.20	45.40	46.69	43.34	42.70	37.88	39.42	40.57	39.14	34.42	-179.75	82.05	81.39	80.61	82.10	80.20	78.19	79.61	80.68	75.37	77.66	76.28	78.76	77.12	74.35	75.19	74.96	71.46	72.39	75.59	74.60	75.01	75.25	78.74	76.93	75.15	75.63	75.23	77.06	76.36	51.44	54.33	97.72	74.87	63.29	76.77	76.70	75.30	76.50	76.10	77.23	63.99	75.00	63.30	61.93	63.32	59.30	63.13	56.81	60.82	65.24	63.37	62.71	63.36	63.43	64.85	65.29	67.99	66.00	69.51	69.79	68.53	66.31	68.34	67.38	70.38	70.21	72.10	71.63	68.31	81.24	73.16	70.90	72.78	56.84	71.92	73.43	74.14	71.70	66.45	71.57	74.06	72.21	73.10	73.45	73.49	74.06	78.29	77.17	76.66	76.27	78.21	78.13	78.10	79.73	81.25	78.17	72.78	75.90
1.35	1.46	1.47	1.61	1.59	1.65	1.63	1.8	1.75	1.84	1.94	2.03	1.84	1.99	2.01	2.16	2.06	2.26	2.34	2.35	2.09	2.39	2.31	2.43	2.3	2.63	2.66	2.93	2.78	2.97	2.94	3.16	2.82	3.09	3.29	3.77	3.38	3.65	3.83	4.32	4.02	4.43	4.58	4.9	4.3	4.69	4.84	4.92	4.19	3.97	4.45	4.93	4.49	4.54	4.62	4.4	4.48	4.86	4.17	4.46	4.09	4.31	4.18	4.29	4.07	4.33	3.87	4.38	4.36	4.56	4.56	4.7	4.58	4.66	4.47	4.56	4.05	4.55	4.62	5.19	6.21	11.09	8.33	7.65	8.89	9.32	9.05	9.41	8.93	9.51	7.35	8.8	6.76	6.82	6.99	6.71	6.48	6.21	6.42	6.84	5.97	6.14	6.38	6.48	6.04	6.43	7.16	6.68	6.56	6.93	7.08	6.92	6.86	7.05	7.6	7.72	7.8	8.42	8.47	3.37	7.53	6.63	7.95	6.22	7.64	8.37	9.75	9.69	10.57	10.44	11.08	9.99	10.59	11.04	11.73	10.84	12.35	12.43	12.77	11.92	12.15	12.35	13.49	13.08	13.08	13.08	13.08	13.08
0.4	0.47	0.47	0.44	0.48	0.56	0.55	0.53	0.1	0.64	0.64	0.61	0.61	0.17	0.71	0.67	0.68	0.76	0.79	0.77	0.76	0.86	0.86	0.86	0.86	0.97	1	1.04	1.02	1.15	1.2	1.24	1.16	1.32	1.37	1.4	1.3	1.48	1.54	1.57	1.5	1.72	1.84	1.76	1.66	1.82	1.95	1.86	1.63	1.75	1.88	1.89	1.71	1.87	1.62	1.4	1.62	1.77	1.33	1.1	1.37	0.72	1.42	1.12	1.52	1.5	0.94	0.47	1.7	1.68	1.53	-1.63	3.29	1.76	1.09	1.64	1.42	1.55	3.41	6.47	0.3	0.75	0.34	-0.53	1.04	2.02	1.69	1.51	1.74	1.79	1.73	0.91	1.59	0.91	1.12	0.78	1.71	2	0.9	7.32	0.95	0.69	1.83	0.98	1.13	1.21	2.18	-0.6	1.55	1.95	-0.06	-1.05	0.74	1.71	1.95	1.83	2.92	2.67	1.9	2	3.22	3	2.94	-2.09	3.18	1.55	4.57	3.76	4.31	3.94	3.25	3.02	2.82	-5.98	4.75	-1.23	4.76	5.46	3.16	3.74	5.08	4.43	5.79	2.96	-3.84	5.61	6.4	5.68
–	16.34	-1.06	-4.95	9.50	14.88	-0.72	-3.99	-81.70	563.92	-1.40	-4.09	0.66	-71.94	310.47	-4.53	0.15	13.19	2.75	-1.66	-1.94	13.34	0.47	-0.46	0.70	12.50	3.09	4.19	-2.30	13.14	3.73	3.76	-6.28	13.06	3.88	2.49	-7.21	13.69	4.19	2.14	-4.64	14.80	6.62	-3.92	-6.07	9.54	7.33	-4.52	-12.63	7.69	7.66	0.27	-9.48	9.18	-13.39	-13.73	15.99	9.27	-25.00	-16.97	24.43	-47.45	97.22	-21.13	35.71	-1.38	-37.29	-49.68	260.25	-1.64	-9.01	-206.89	-302.09	-46.48	-38.06	49.91	-13.26	9.23	119.99	89.57	-95.39	151.34	-54.61	-255.29	-296.78	94.42	-16.39	-10.60	14.97	3.23	-3.52	-47.48	75.44	-43.13	24.06	-30.52	118.31	17.54	-55.34	717.43	-86.99	-27.84	165.79	-46.50	15.15	7.11	81.24	-127.24	-360.67	25.47	-102.88	1,767.86	-170.36	131.93	14.24	-6.31	59.55	-8.40	-28.80	5.05	61.19	-6.74	-2.03	-171.20	-251.81	-51.40	195.60	-17.71	14.69	-8.49	-17.65	-7.11	-6.50	-311.80	-179.41	-125.84	-488.42	14.55	-42.13	18.56	35.69	-12.84	30.68	-48.78	-229.50	-246.23	14.04	-11.31
0.08	0.08	0.09	0.09	0.09	0.09	0.11	0.11	0.12	0.12	0.13	0.13	0.13	0.13	0.14	0.14	0.14	0.14	0.15	0.15	0.15	0.15	0.17	0.17	0.17	0.17	0.20	0.20	0.21	0.21	0.23	0.23	0.23	0.23	0.27	0.27	0.27	0.27	0.29	0.29	0.29	0.29	0.34	0.34	0.34	0.34	0.35	0.35	0.35	0.35	0.36	0.36	0.36	0.36	0.37	0.37	0.37	0.37	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.38	0.42	0.42	0.42	0.42	0.43	0.43	0.43	0.43	0.44	0.44	0.44	0.44	0.45	0.45	0.45	0.45	0.46	0.46	0.46	0.46	0.47	0.47	0.47	0.47	0.48	0.48	0.48	0.48	0.55	0.55	0.55	0.55	0.61	0.61	0.61	0.61	0.65	0.65	0.65	0.65	0.69	0.69	0.69	0.69	0.73	0.73	0.73	0.73	0.77	0.77	0.77	0.77	0.81	0.81	0.81	0.81	0.85	0.85	-	-	-
–	–	28.57	–	–	–	11.11	–	20.00	–	8.33	–	–	–	7.69	–	–	–	7.14	–	–	–	13.33	–	–	–	17.65	–	5.00	–	9.52	–	–	–	17.39	–	–	–	7.41	–	–	–	17.24	–	–	–	2.94	–	–	–	2.86	–	–	–	2.78	–	–	–	2.70	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	10.53	–	–	–	2.38	–	–	–	2.33	–	–	–	2.27	–	–	–	2.22	–	–	–	2.17	–	–	–	2.13	–	–	–	14.58	–	–	–	10.91	–	–	–	6.56	–	–	–	6.15	–	–	–	5.80	–	–	–	5.48	–	–	–	5.19	–	–	–	4.94	–	–	–	–
2.37	2.37	2.37	2.37	2.36	2.36	2.36	2.36	2.37	2.31	2.31	2.19	2.29	2.3	2.27	2.42	2.55	2.55	2.56	2.55	2.53	2.52	2.53	2.58	2.52	2.49	2.47	2.48	2.48	2.48	2.47	2.45	2.45	2.45	2.44	2.42	2.43	2.41	2.39	2.39	2.36	2.35	2.34	2.36	2.35	2.33	2.31	2.3	2.29	2.32	2.27	2.26	2.26	2.26	2.26	2.24	2.23	2.23	2.27	2.22	2.21	2.24	2.2	2.19	2.19	2.19	2.19	2.18	2.18	2.19	2.19	2.18	2.17	2.15	2.13	2.11	2.11	2.11	2.11	2.75	3.14	3.13	3.08	3.08	3.1	3.11	3.09	3.07	3.08	3.07	3.08	3.07	3.02	3.01	2.96	2.96	2.97	2.91	2.91	2.89	2.85	2.85	2.84	2.81	2.8	2.79	2.79	2.76	2.77	2.75	2.73	2.72	2.71	2.7	2.68	2.63	2.6	2.59	2.57	2.61	2.54	2.54	2.54	2.53	2.54	2.54	2.54	2.54	2.54	2.54	2.54	2.55	2.54	2.54	2.55	2.5	2.54	2.54	2.54	2.54	2.53	2.51	2.5	2.49	2.49	2.49	2.49	2.49

Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Gross Margin

EBIT and EBIT Margin

Net Income and Earnings Per Share (EPS)

Shares Outstanding

Analyst Estimates

API Docs Get API Key

Merck & Co stock margins

The Merck & Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Merck & Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Merck & Co.

3 Years
5 Years
10 Years
25 Years
Max

Gross margin

EBIT margin

Profit margin

Details

API Docs Get API Key

Merck & Co Stock Sales Revenue, EBIT, Earnings per Share

The Merck & Co earnings per share therefore indicates how much revenue Merck & Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

3 Years
5 Years
10 Years
25 Years
Max

Sales per Share

EBIT per share

Earnings per Share

Details

API Docs Get API Key

Merck & Co business model

The company Merck & Co Inc has a long history. It was founded in 1891 by the German pharmacist Friedrich Jacob Merck and is now based in Kenilworth, New Jersey, USA. The company has evolved over time into a globally operating company in the pharmaceutical and chemical industry. Merck & Co Inc's business model is based on the development, production, and marketing of medicines and products for the healthcare industry. The company collaborates with other partners such as universities, other companies, and governments to achieve the best possible scientific progress. Research and development play a very important role in this. Merck is divided into three main areas: The Human Health division, which specializes in the development of prescription drugs and products to improve human health. The second division is Animal Health, which focuses on animal medicines and care products. The third division, Life Science (formerly MilliporeSigma), is dedicated to the development of products and services for biopharmaceutical research and production to facilitate the discovery and manufacturing of medicines. Merck & Co Inc. offers a wide range of products, ranging from prescription medicines to specialty chemicals. Some of the most well-known drugs include Januvia for the treatment of type 2 diabetes and Keytruda, an immuno-oncology drug used in the treatment of various types of cancer. Other well-known drugs from Merck & Co Inc. include Gardasil for the prevention of HPV infections, Propecia for the treatment of male pattern hair loss, and Zetia for the treatment of high cholesterol. The company is extremely innovative and has made significant advances in pharmaceutical research in recent decades. Merck & Co Inc. has won numerous awards over the years, including the "2018 Australian Financial Review Boss Most Innovative Companies Award" and the "2018 Global Energy Award for Technology Innovation". Merck & Co Inc. operates worldwide and has subsidiaries and partnerships in many countries. The company has about 69,000 employees and distributes its products in over 140 countries. Merck & Co Inc.'s products are typically prescription-only and prescribed by doctors and professionals. Overall, Merck & Co Inc. is a company with an impressive history that is now one of the leading companies in the pharmaceutical and chemical industry. Thanks to its innovation and its consistent focus on the needs of patients and healthcare professionals, it is able to successfully meet challenges in the healthcare industry and set new standards.

API Docs Get API Key

Merck & Co SWOT Analysis

Strengths

Merck & Co Inc, a leading pharmaceutical company, possesses the following strengths:

Strong brand reputation and recognition worldwide
Extensive experience and expertise in drug development and research
Robust portfolio of patented drugs and intellectual property
Broad geographical presence, with operations in numerous countries
Diverse product offerings across multiple therapeutic areas

Merck & Co Inc faces the following weaknesses:

Dependency on a limited number of flagship drugs for significant revenue
Relatively high research and development costs
Vulnerability to generic competition as patents expire
Regulatory challenges and delays in drug approvals
Potential exposure to litigation related to product safety and side effects

Merck & Co Inc can explore the following opportunities:

Expansion into emerging markets with growing healthcare needs
Investment in research and development of innovative drugs and therapies
Strategic collaborations and partnerships for joint ventures and licensing
Advancements in technology for drug delivery and precision medicine
Increasing demand for personalized healthcare solutions

Merck & Co Inc faces the following threats:

Intense competition from other major pharmaceutical companies
Economic and political fluctuations impacting global markets
Stringent regulations and compliance requirements
Potential disruption caused by unforeseen events, such as pandemics
Negative public perception and skepticism towards the pharmaceutical industry

Weaknesses

Merck & Co Inc faces the following weaknesses:

Dependency on a limited number of flagship drugs for significant revenue
Relatively high research and development costs
Vulnerability to generic competition as patents expire
Regulatory challenges and delays in drug approvals
Potential exposure to litigation related to product safety and side effects

Merck & Co Inc can explore the following opportunities:

Expansion into emerging markets with growing healthcare needs
Investment in research and development of innovative drugs and therapies
Strategic collaborations and partnerships for joint ventures and licensing
Advancements in technology for drug delivery and precision medicine
Increasing demand for personalized healthcare solutions

Merck & Co Inc faces the following threats:

Intense competition from other major pharmaceutical companies
Economic and political fluctuations impacting global markets
Stringent regulations and compliance requirements
Potential disruption caused by unforeseen events, such as pandemics
Negative public perception and skepticism towards the pharmaceutical industry

Opportunities

Merck & Co Inc can explore the following opportunities:

Expansion into emerging markets with growing healthcare needs
Investment in research and development of innovative drugs and therapies
Strategic collaborations and partnerships for joint ventures and licensing
Advancements in technology for drug delivery and precision medicine
Increasing demand for personalized healthcare solutions

Merck & Co Inc faces the following threats:

Intense competition from other major pharmaceutical companies
Economic and political fluctuations impacting global markets
Stringent regulations and compliance requirements
Potential disruption caused by unforeseen events, such as pandemics
Negative public perception and skepticism towards the pharmaceutical industry

Threats

Merck & Co Inc faces the following threats:

Intense competition from other major pharmaceutical companies
Economic and political fluctuations impacting global markets
Stringent regulations and compliance requirements
Potential disruption caused by unforeseen events, such as pandemics
Negative public perception and skepticism towards the pharmaceutical industry

API Docs Get API Key

Merck & Co Segments

Merck & Co Revenue by Segment (1/3)

3 Years
5 Years
10 Years
Max

Other pharmaceutical

Keytruda

Gardasil/Gardasil 9

Janumet

Januvia

Gardasil

ProQuad/M-M-R II/Varivax

Zepatier

Isentress

Remicade

Pneumovax 23

Vytorin

Maxalt

Pneumovax

Isentress/Isentress HD

Adempas

Implanon/Nexplanon

Cancidas

Nasonex

Cubicin

Zetia

Implanon

Emend

Noxafil

Dulera

Primaxin

Temodar

Cerazette

Cosopt/Trusopt

Zostavax

Claritin Rx

Fosamax

Invanz

Bridion

Atozet

Proscar

Integrilin

RotaTeq

Avelox

NuvaRing

Remeron

Vasotec/Vaseretic

Clarinex

Zocor

Asmanex

Propecia

PegIntron

Follistim AQ

Victrelis

Singulair

Cozaar/Hyzaar

Arcoxia

Simponi

Details

Date

Other pharmaceutical

Keytruda

Gardasil/Gardasil 9

Janumet

Januvia

Gardasil

ProQuad/M-M-R II/Varivax

Zepatier

Isentress

Remicade

Pneumovax 23

Vytorin

Maxalt

Pneumovax

Isentress/Isentress HD

Adempas

Implanon/Nexplanon

Cancidas

Nasonex

Cubicin

Zetia

Implanon

Emend

Noxafil

Dulera

Primaxin

Temodar

Cerazette

Cosopt/Trusopt

Zostavax

Claritin Rx

Fosamax

Invanz

Bridion

Atozet

Proscar

Integrilin

RotaTeq

Avelox

NuvaRing

Remeron

Vasotec/Vaseretic

Clarinex

Zocor

Asmanex

Propecia

PegIntron

Follistim AQ

Victrelis

Singulair

Cozaar/Hyzaar

Arcoxia

Simponi

Jan 1, 2012

0 USD

1.66 B USD

4.09 B USD

1.63 B USD

1.27 B USD

0 USD

1.52 B USD

2.08 B USD

0 USD

1.75 B USD

638 M USD

580 M USD

0 USD

619 M USD

1.27 B USD

0 USD

2.57 B USD

348 M USD

489 M USD

258 M USD

207 M USD

384 M USD

917 M USD

271 M USD

444 M USD

651 M USD

244 M USD

676 M USD

445 M USD

261 M USD

0 USD

217 M USD

211 M USD

601 M USD

201 M USD

623 M USD

232 M USD

192 M USD

393 M USD

383 M USD

185 M USD

424 M USD

653 M USD

468 M USD

502 M USD

3.85 B USD

1.28 B USD

453 M USD

331 M USD

Jan 1, 2014

0 USD

55 M USD

0 USD

2.07 B USD

3.93 B USD

1.74 B USD

1.39 B USD

0 USD

1.67 B USD

2.37 B USD

746 M USD

1.52 B USD

0 USD

502 M USD

681 M USD

1.1 B USD

0 USD

2.65 B USD

0 USD

553 M USD

402 M USD

460 M USD

329 M USD

350 M USD

0 USD

257 M USD

765 M USD

0 USD

470 M USD

529 M USD

340 M USD

0 USD

659 M USD

0 USD

723 M USD

193 M USD

0 USD

232 M USD

258 M USD

0 USD

264 M USD

381 M USD

412 M USD

153 M USD

1.09 B USD

806 M USD

519 M USD

689 M USD

Jan 1, 2015

4.55 B USD

566 M USD

1.91 B USD

2.15 B USD

3.86 B USD

0 USD

1.51 B USD

0 USD

1.51 B USD

1.79 B USD

542 M USD

1.25 B USD

0 USD

588 M USD

573 M USD

858 M USD

1.13 B USD

2.53 B USD

0 USD

535 M USD

487 M USD

536 M USD

313 M USD

312 M USD

0 USD

749 M USD

0 USD

359 M USD

569 M USD

353 M USD

0 USD

610 M USD

0 USD

732 M USD

0 USD

187 M USD

217 M USD

0 USD

183 M USD

182 M USD

383 M USD

0 USD

931 M USD

667 M USD

471 M USD

690 M USD

Jan 1, 2016

4.7 B USD

1.4 B USD

2.17 B USD

2.2 B USD

3.91 B USD

0 USD

1.64 B USD

555 M USD

1.39 B USD

1.27 B USD

641 M USD

1.14 B USD

0 USD

606 M USD

558 M USD

537 M USD

1.09 B USD

2.56 B USD

0 USD

549 M USD

595 M USD

436 M USD

297 M USD

283 M USD

0 USD

685 M USD

0 USD

284 M USD

561 M USD

482 M USD

0 USD

652 M USD

0 USD

777 M USD

0 USD

186 M USD

0 USD

355 M USD

0 USD

915 M USD

511 M USD

450 M USD

766 M USD

Jan 1, 2017

1.25 B USD

2.31 B USD

2.16 B USD

2.15 B USD

0 USD

1.68 B USD

1.66 B USD

0 USD

837 M USD

821 M USD

751 M USD

0 USD

565 M USD

500 M USD

496 M USD

422 M USD

387 M USD

382 M USD

352 M USD

0 USD

342 M USD

309 M USD

287 M USD

280 M USD

271 M USD

0 USD

246 M USD

0 USD

241 M USD

239 M USD

225 M USD

0 USD

204 M USD

0 USD

197 M USD

0 USD

174 M USD

0 USD

40 M USD

18 M USD

0 USD

Merck & Co Revenue by Segment (2/3)

3 Years
5 Years
10 Years
25 Years
Max

Remicade and Simponi

Details

Merck & Co Revenue by Segment (3/3)

3 Years
5 Years
10 Years
Max

Segment

Operating segments

Segment One

Pharmaceutical

Pharmaceutical segment

All Other Segments

All Other

Other pharmaceutical

Other segments

Primary Care and Women's Health

Diversified Brands

Vaccines

Other

Oncology

Hospital and Specialty

Other Miscellaneous

Details

Merck & Co Revenue by Region

3 Years
5 Years
10 Years
Max

United States

Int’l

Europe, Middle East and Africa

Europe, Middle East, and Africa

China

Asia Pacific

Latin America

Japan

Asia Pacific (other than China and Japan)

Asia Pacific (other than Japan and China)

Other Countries

Intu2019l

Details

API Docs Get API Key

Merck & Co Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

API Docs Get API Key

Merck & Co historical P/E ratio, EBIT multiple, and P/S ratio

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Merck & Co's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Merck & Co's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Merck & Co's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Merck & Co grows earnings faster than its peers.

API Docs Get API Key

Merck & Co annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

API Docs Get API Key

Merck & Co shares outstanding

The number of shares was Merck & Co in 2025 — This indicates how many shares 2.507 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

3 Years
5 Years
10 Years
25 Years
Max

Number of stocks

Details

API Docs Get API Key

Merck & Co stock splits

In Merck & Co's history, there have been no stock splits.

API Docs Get API Key

Merck & Co Dividend History

37 years of dividend payments · 15 consecutive increases

YearAnnual DividendYoY ChangePayments

20260.85USDYTD—1×

Mar 16, 20260.85USD 0.0%1/1

20253.28USD↑ 5.1%4×

Mar 17, 20250.81USD 0.0%1/4

Jun 16, 20250.81USD 0.0%2/4

Sep 15, 20250.81USD 0.0%3/4

Dec 15, 20250.85USD↑ 4.9%4/4

20243.12USD↑ 5.4%4×

20232.96USD↑ 5.7%4×

20222.8USD↑ 6.1%4×

20212.64USD↑ 6.5%4×

20202.48USD↑ 9.7%4×

20192.26USD↑ 13.6%4×

20181.99USD↑ 5.3%4×

20171.89USD↑ 2.2%4×

API Docs Get API Key

Merck & Co dividend history and estimates

In 2025, Merck & Co paid a dividend amounting to 3.28 USD. Dividend means that Merck & Co distributes a portion of its profits to its owners.

3 Years
5 Years
10 Years
25 Years
Max

Dividend

Dividend (Estimate)

Details

API Docs Get API Key

Merck & Co dividend payout ratio

In 2025, Merck & Co had a payout ratio of 55.59%. The payout ratio indicates the percentage of the company's profits that Merck & Co distributes as dividends.

3 Years
5 Years
10 Years
25 Years
Max

Payout ratio

Details

API Docs Get API Key

Current Merck & Co forecasts and price targets in March 2026

Δ MOM Price Target	4.82 %
Buy	61.76 % (21)
Hold	38.24 % (13)
Sell	null % (0)
12M Price Target	121.89
Last Price	115.82
Currency	USD
12M Return Potential	5.24 %
LTM Return	0 %

API Docs Get API Key

Merck & Co Earnings Calls

2025

Oct 30Q3 2025 Earnings Call Transcript

PDF Audio

Jul 29Q2 2025 Earnings Call Transcript

PDF Audio

Apr 24Q1 2025 Earnings Call Transcript

PDF Audio

Feb 4Q4 2024 Earnings Call Transcript

Audio

2024

Jul 30Q2 2024 Earnings Call Transcript

Audio

Apr 25Q1 2024 Earnings Call Transcript

Audio

Merck & Co Earnings Estimates

Date	EPS estimate	Revenue Estimate	Quarterly report
2/3/2026	2.03USD	16.36 BUSD	2025 Q4
4/25/2024	1.98USD	15.15 BUSD	2024 Q1
2/1/2024	0.13USD	14.66 BUSD	2023 Q4
8/1/2023	1.88USD	14.93 BUSD	2023 Q2
4/27/2023	1.78USD	14.35 BUSD	2023 Q1
2/2/2023	1.54USD	13.83 BUSD	2022 Q4
10/27/2022	1.72USD	14.29 BUSD	2022 Q3
7/28/2022	1.72USD	14.11 BUSD	2022 Q2
4/28/2022	1.85USD	14.9 BUSD	2022 Q1
2/3/2022	1.54USD	13.36 BUSD	2021 Q4
10/28/2021	1.56USD	12.52 BUSD	2021 Q3
7/29/2021	1.32USD	11.26 BUSD	2021 Q2
4/29/2021	1.64USD	12.85 BUSD	2021 Q1
2/4/2021	1.39USD	12.87 BUSD	2020 Q4
10/27/2020	1.45USD	12.4 BUSD	2020 Q3
7/31/2020	1.05USD	10.54 BUSD	2020 Q2
4/28/2020	1.36USD	11.63 BUSD	2020 Q1
2/5/2020	1.16USD	12.16 BUSD	2019 Q4
10/29/2019	1.25USD	11.81 BUSD	2019 Q3
7/30/2019	1.17USD	11.12 BUSD	2019 Q2
4/30/2019	1.07USD	10.63 BUSD	2019 Q1
2/1/2019	1.04USD	11.15 BUSD	2018 Q4
10/25/2018	1.15USD	11.04 BUSD	2018 Q3
7/27/2018	1.04USD	10.45 BUSD	2018 Q2
5/1/2018	1.01USD	10.26 BUSD	2018 Q1
2/2/2018	0.94USD	10.65 BUSD	2017 Q4
10/27/2017	1.04USD	10.7 BUSD	2017 Q3
7/28/2017	0.88USD	9.89 BUSD	2017 Q2
5/2/2017	0.84USD	9.39 BUSD	2017 Q1
2/2/2017	0.9USD	10.37 BUSD	2016 Q4
10/25/2016	1USD	10.33 BUSD	2016 Q3
7/29/2016	0.92USD	9.93 BUSD	2016 Q2
5/5/2016	0.86USD	9.61 BUSD	2016 Q1
2/3/2016	0.92USD	10.51 BUSD	2015 Q4
10/27/2015	0.92USD	10.23 BUSD	2015 Q3
7/28/2015	0.82USD	9.95 BUSD	2015 Q2
4/28/2015	0.75USD	9.2 BUSD	2015 Q1
2/4/2015	0.86USD	10.66 BUSD	2014 Q4
10/27/2014	0.89USD	10.82 BUSD	2014 Q3
7/29/2014	0.82USD	10.76 BUSD	2014 Q2
4/29/2014	0.79USD	10.6 BUSD	2014 Q1
2/5/2014	0.9USD	11.53 BUSD	2013 Q4
10/28/2013	0.88USD	11.29 BUSD	2013 Q3
7/30/2013	0.83USD	11.39 BUSD	2013 Q2
5/1/2013	0.8USD	11.26 BUSD	2013 Q1
2/1/2013	0.82USD	11.68 BUSD	2012 Q4
10/26/2012	0.93USD	11.75 BUSD	2012 Q3
7/27/2012	1.02USD	12.33 BUSD	2012 Q2
4/27/2012	0.99USD	11.99 BUSD	2012 Q1
2/2/2012	0.96USD	12.72 BUSD	2011 Q4
10/28/2011	0.92USD	11.79 BUSD	2011 Q3
7/29/2011	0.96USD	11.96 BUSD	2011 Q2
4/29/2011	0.85USD	11.54 BUSD	2011 Q1
2/3/2011	0.84USD	11.7 BUSD	2010 Q4
10/29/2010	0.83USD	11.41 BUSD	2010 Q3
7/30/2010	0.83USD	11.63 BUSD	2010 Q2
5/4/2010	0.76USD	11.35 BUSD	2010 Q1
2/16/2010	0.79USD	9.84 BUSD	2009 Q4
10/22/2009	0.83USD	6.1 BUSD	2009 Q3
7/21/2009	0.78USD	5.93 BUSD	2009 Q2
4/21/2009	0.78USD	5.85 BUSD	2009 Q1
2/3/2009	0.75USD	6.07 BUSD	2008 Q4
10/22/2008	0.8USD	6.07 BUSD	2008 Q3
7/21/2008	0.84USD	6.14 BUSD	2008 Q2
4/21/2008	0.87USD	6.21 BUSD	2008 Q1
1/30/2008	0.74USD	6.39 BUSD	2007 Q4
10/22/2007	0.69USD	6.15 BUSD	2007 Q3
7/23/2007	0.73USD	5.86 BUSD	2007 Q2
4/19/2007	0.85USD	5.44 BUSD	2007 Q1
1/30/2007	0.51USD	5.46 BUSD	2006 Q4
10/20/2006	0.51USD	5.05 BUSD	2006 Q3
7/24/2006	0.66USD	5.54 BUSD	2006 Q2
4/20/2006	0.73USD	5.56 BUSD	2006 Q1
1/31/2006	0.63USD	5.73 BUSD	2005 Q4
10/24/2005	0.63USD	5.54 BUSD	2005 Q3
7/21/2005	0.63USD	5.57 BUSD	2005 Q2
4/21/2005	0.59USD	5.36 BUSD	2005 Q1
1/25/2005	0.51USD	5.38 BUSD	2004 Q4
10/21/2004	0.72USD	6.02 BUSD	2004 Q3
7/21/2004	0.8USD	5.94 BUSD	2004 Q2
4/22/2004	0.73USD	5.83 BUSD	2004 Q1
1/27/2004	0.62USD	5.61 BUSD	2003 Q4
10/22/2003	0.85USD	6.01 BUSD	2003 Q3
7/21/2003	0.85USD	13.83 BUSD	2003 Q2
4/21/2003	0.76USD	13.32 BUSD	2003 Q1
1/28/2003	0.84USD	13.85 BUSD	2002 Q4
10/18/2002	0.83USD	13.04 BUSD	2002 Q3
7/19/2002	0.77USD	12.94 BUSD	2002 Q2
4/18/2002	0.71USD	12.51 BUSD	2002 Q1

...

EESG©

73/100

Environment

Social

Governance

Environment

Scope 1 - Direct Emissions718,400

Scope 2 - Indirect emissions from purchased energy356,900

Scope 3 - Indirect emissions within the value chain6,184,100

Total CO₂ emissions1,075,300

CO₂ reduction strategy

Coal energy

Nuclear power

Animal experiments

Fur & Leather—

Pesticides—

Palm Oil—

Tobacco

Genetically modified organisms

Climate concept—

Sustainable forestry—

Recycling regulations

Environmentally friendly packaging

Hazardous substances

Fuel consumption and efficiency

Water consumption and efficiency

Social

Percentage of female employees51

Percentage of women in management—

Percentage of Asian employees18

Share of Asian management15

Percentage of Hispanic/Latino employees7

Hispano/Latino Management share6

Percentage of Black employees9

Black Management Share6

Percentage of white employees64

White Management Share71

Adult content

Alcohol

Weapons—

Firearms

Gambling

Military contracts

Human rights concept

Privacy concept—

Occupational health and safety

Catholic

Governance (Corporate Governance)

Environmental reporting

Stakeholder Engagement

Call Back Policies

Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

API Docs Get API Key

Merck & Co shareholders

%	Name	Stocks	Change	Date
10.04207%	The Vanguard Group, Inc.	251,754,614	+356,586	6/30/2025
5.69540%	BlackRock Institutional Trust Company, N.A.	142,783,764	-4,514,233	6/30/2025
4.72652%	State Street Investment Management (US)	118,493,864	-2,035,776	6/30/2025
3.06568%	Wellington Management Company, LLP	76,856,492	-4,813,159	6/30/2025
2.35152%	Geode Capital Management, L.L.C.	58,952,681	-704,589	6/30/2025
2.14860%	Charles Schwab Investment Management, Inc.	53,865,466	+4,636,183	6/30/2025
1.44042%	Norges Bank Investment Management (NBIM)	36,111,289	+1,131,404	6/30/2025
1.13606%	Fidelity Management & Research Company LLC	28,481,062	+229,467	6/30/2025
0.99775%	Fisher Investments	25,013,697	+567,900	6/30/2025
0.90891%	BlackRock Asset Management Ireland Limited	22,786,361	+764,142	6/30/2025
0.80798%	BofA Global Research (US)	20,255,969	-1,213,213	6/30/2025
0.78710%	Morgan Stanley Smith Barney LLC	19,732,682	-164,311	6/30/2025
0.77794%	Legal & General Investment Management Ltd.	19,503,045	-252,263	6/30/2025
0.77607%	Arrowstreet Capital, Limited Partnership	19,456,096	+5,094,088	6/30/2025
0.75164%	Northern Trust Investments, Inc.	18,843,507	-840,801	6/30/2025
0.67868%	JP Morgan Asset Management	17,014,423	+5,242,724	6/30/2025
0.63588%	Amundi Asset Management, SAS	15,941,505	+4,728,893	6/30/2025
0.61056%	UBS Financial Services, Inc.	15,306,733	-4,352,191	6/30/2025
0.60298%	BlackRock Investment Management (UK) Ltd.	15,116,704	-1,688,945	6/30/2025
0.58552%	Franklin Advisers, Inc.	14,678,914	+3,922,138	6/30/2025
0.55859%	State Farm Insurance Companies	14,003,819	+39,700	6/30/2025
0.54129%	Mellon Investments Corporation	13,570,248	-119,440	6/30/2025
0.52634%	Parametric Portfolio Associates LLC	13,195,294	-205,423	6/30/2025
0.50175%	Columbia Threadneedle Investments (US)	12,578,976	+318,746	6/30/2025
0.47594%	Goldman Sachs Asset Management, L.P.	11,931,861	+288,042	6/30/2025
0.43659%	Nordea Funds Oy	10,945,187	+209,759	9/30/2025
0.42374%	Dimensional Fund Advisors, L.P.	10,623,142	-291,085	6/30/2025
0.41355%	D. E. Shaw & Co., L.P.	10,367,789	+1,056,063	6/30/2025
0.36423%	Harris Associates L.P.	9,131,318	+1,661,958	6/30/2025
0.35921%	BlackRock Financial Management, Inc.	9,005,307	-816,928	6/30/2025
0.35843%	Invesco Capital Management LLC	8,985,879	+1,563,660	6/30/2025
0.35318%	AllianceBernstein L.P.	8,854,176	-1,382,219	6/30/2025
0.35280%	Wells Fargo Advisors	8,844,774	-700,955	6/30/2025
0.35051%	AQR Capital Management, LLC	8,787,272	+1,029,454	6/30/2025
0.34729%	Barrow Hanley Global Investors	8,706,682	+915,584	6/30/2025
0.33283%	Swedbank Robur Fonder AB	8,344,126	+469,360	9/30/2025
0.32451%	Aristotle Capital Management, LLC	8,135,552	-328,197	6/30/2025
0.32377%	Two Sigma Investments, LP	8,116,948	+2,627,647	6/30/2025
0.31732%	UBS Asset Management (Switzerland)	7,955,317	+3,249,638	6/30/2025
0.31099%	BlackRock (Netherlands) B.V.	7,796,533	-446,079	6/30/2025
0.30974%	Managed Account Advisors LLC	7,765,165	-1,849,898	6/30/2025
0.30779%	DWS Investment GmbH	7,716,176	-1,679,711	6/30/2025
0.30775%	Invesco Advisers, Inc.	7,715,351	+101,953	6/30/2025
0.30622%	California Public Employees' Retirement System	7,677,010	-615,782	6/30/2025
0.30497%	Nuveen LLC	7,645,685	-3,045,423	6/30/2025
0.30385%	Schweizerische Nationalbank	7,617,551	+482,700	6/30/2025
0.30252%	UBS Asset Management (UK) Ltd.	7,584,228	+742,842	6/30/2025
0.29382%	Sumitomo Mitsui Trust Bank, Limited	7,366,188	-70,408	9/30/2025
0.29348%	MFS Investment Management	7,357,623	-145,998	9/30/2025
0.28388%	T. Rowe Price Associates, Inc.	7,116,847	-956,759	6/30/2025
0.26503%	BNP Paribas Securities Corp. North America	6,644,333	-1,561,155	6/30/2025
0.26496%	BlackRock Investment Management, LLC	6,642,533	+214,581	6/30/2025
0.26362%	Lazard Asset Management, L.L.C.	6,609,067	+1,590,438	6/30/2025
0.26302%	Stifel, Nicolaus & Company, Incorporated	6,594,011	+368,394	6/30/2025
0.25806%	Grantham Mayo Van Otterloo & Co LLC	6,469,573	-217,023	6/30/2025
0.25805%	HSBC Global Asset Management (UK) Limited	6,469,409	-174,631	6/30/2025
0.24378%	Goldman Sachs & Company, Inc.	6,111,493	+3,870,864	6/30/2025
0.23501%	PNC Investments LLC	5,891,739	-94,760	6/30/2025
0.23232%	Franklin Mutual Advisers, LLC	5,824,367	+786,767	6/30/2025
0.22544%	DWS Investments UK Limited	5,651,745	-370,137	6/30/2025
0.22455%	Principal Global Investors (Equity)	5,629,591	+159	6/30/2025
0.22371%	RBC Capital Markets Wealth Management	5,608,490	-22,436	6/30/2025
0.22065%	National Pension Service	5,531,803	+258,320	6/30/2025
0.21925%	Assenagon Asset Management S.A.	5,496,664	+3,618,532	9/30/2025
0.21815%	UBS Asset Management (Americas) LLC	5,469,061	+39,085	6/30/2025
0.21735%	Morgan Stanley & Co. LLC	5,449,055	-139,390	6/30/2025
0.21286%	LSV Asset Management	5,336,436	-128,994	6/30/2025
0.20890%	Pacer Advisors, Inc.	5,237,153	-804,609	9/30/2025
0.20361%	Beutel, Goodman & Company Ltd.	5,104,436	+679,339	6/30/2025
0.20143%	First Trust Advisors L.P.	5,049,741	+2,211,568	6/30/2025
0.19895%	Raymond James & Associates, Inc.	4,987,585	-4,950,353	6/30/2025
0.19856%	Mitsubishi UFJ Asset Management Co., Ltd.	4,977,819	+297,714	6/30/2025
0.19841%	Citi Investment Research (US)	4,974,132	-1,108,550	6/30/2025
0.19697%	Corient Private Wealth LLC	4,937,948	+2,277,088	6/30/2025
0.19525%	BNY Mellon Asset Management	4,894,862	-918,033	6/30/2025
0.19400%	ClearBridge Investments, LLC	4,863,538	-1,040,451	6/30/2025
0.18866%	Thornburg Investment Management, Inc.	4,729,641	+1,642,835	6/30/2025
0.18849%	Putnam Investment Management, L.L.C.	4,725,443	+613,044	6/30/2025
0.18056%	JPMorgan Private Bank (United States)	4,526,740	-1,930,674	6/30/2025
0.17679%	Victory Capital Management Inc.	4,432,168	-34,832	6/30/2025
0.17644%	Northern Trust Global Investments	4,423,280	-615,552	6/30/2025
0.17631%	Caisse de Depot et Placement du Quebec	4,420,111	+104,701	6/30/2025
0.17478%	Barclays Bank PLC	4,381,855	+319,433	6/30/2025
0.17465%	J.P. Morgan Securities LLC	4,378,354	+575,386	6/30/2025
0.16667%	Acadian Asset Management LLC	4,178,385	+1,583,692	6/30/2025
0.16465%	BlackRock Japan Co., Ltd.	4,127,666	-72,974	6/30/2025
0.16391%	Rhumbline Advisers Ltd. Partnership	4,109,208	-383,775	6/30/2025
0.16336%	Deka Investment GmbH	4,095,355	+37,306	6/30/2025
0.16214%	Capital International Investors	4,064,975	-748,830	6/30/2025
0.16208%	California State Teachers Retirement System	4,063,309	+18,699	6/30/2025
0.16045%	Qube Research & Technologies Ltd	4,022,464	+589,052	6/30/2025
0.15542%	UBS Fund Management (Switzerland) AG	3,896,435	+337,797	6/30/2025
0.15258%	PGIM Quantitative Solutions LLC	3,825,240	+478,108	6/30/2025
0.15062%	Aperio Group, LLC	3,776,151	-371,403	6/30/2025
0.15048%	American Century Investment Management, Inc.	3,772,459	+721,844	6/30/2025
0.15025%	Hightower Advisors, LLC	3,766,789	+67,829	6/30/2025
0.14940%	Envestnet Asset Management, Inc.	3,745,382	-1,299,458	6/30/2025
0.14909%	Northern Trust Global Investments Limited	3,737,739	-355,737	6/30/2025
0.14683%	T. Rowe Price International Ltd	3,681,143	-11,083	6/30/2025
0.14507%	CPP Investment Board	3,637,000	-185,309	6/30/2025

...

API Docs Get API Key

Merck & Co Executives and Management Board

Mr. Robert Davis

(58)

Chairman of the Board, President, Chief Executive Officer · since 2014

Compensation23.19 MUSD

Compensation23.19 M USD

Mr. Chirfi Guindo

(59)

Senior Vice President, Chief Marketing Officer - Human Health

13.94 MUSD

Compensation13.94 M USD

Ms. Betty Larson

(49)

Chief Human Resources Officer, Executive Vice President

11.26 MUSD

Compensation11.26 M USD

Dr. Dean Li

(63)

Executive Vice President, President - Merck Research Laboratories · since 2021

10.09 MUSD

Compensation10.09 M USD

Mr. Richard Deluca

(62)

Executive Vice President, President - Merck Animal Health

9.1 MUSD

Compensation9.1 M USD

API Docs Get API Key

Merck & Co Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite

30 companies

#	Name	1M	3M	6M	1Y	2Y	Trend
1	AstraZeneca Supplier	0,24	0,94	0,78	0,77	0,73

#	Name	1M	3M	6M	1Y	2Y
1	SUSE Supplier	0,60	0,83	-0,13	0,04	—
2	DKSH Holding AG	—	—	—	—	—
3	908 Devices Supplier	0,36	0,60	-0,15	-0,36	—
4	Daiichi Sankyo Company, Limited Supplier	0,35	0,46	0,00	0,05	—
5	Ono Pharmaceutical Co., Ltd.	0,35	—	—	—	—

API Docs Get API Key

Merck & Co Research

Soon

Deep-dive analyses, investment theses, and proprietary research — curated by Eulerpool.

Research reports are coming soon

We're building institutional-grade equity research for Merck & Co and thousands of other companies.

Most common questions regarding Merck & Co

The business model of Merck & Co Inc is centered around the development, manufacturing, and marketing of innovative pharmaceutical products and vaccines. Merck's primary aim is to improve and save lives by addressing unmet medical needs. Through rigorous research and development, the company focuses on discovering novel therapies and delivering them to patients worldwide. Merck operates across various therapeutic areas, including oncology, infectious diseases, vaccines, cardiovascular health, and more. By combining scientific expertise with a strong commitment to patients and healthcare professionals, Merck continually strives to advance medical science and make a positive impact on global health.

API Docs Get API Key

Fair ValuePRO

98.52 USD

Over-/UndervaluationPRO

26.0% undervalued

Expected Return

8.34 %

Sector

Health

Industry

Pharmaceuticals

Number of shares

2,507,000,000

Employees

71,000

Revenue per Employee

915,647.89 USD

Revenue growth Ø5 years

5.95 %

EBIT growth Ø5 years

11.42 %

Net Income growth Ø5 years

6.94 %

Website merck.com

Country

United States 🇺🇸

Currency

USD

Initial public offering

Jun 15, 1946

ISIN

US58933Y1055

Cusip

58933Y105

Sedol

2778844

Market capitalization

301.34 B USDMega Cap

52-Week Range

115.56–123.54USD

Merck & Co Directors Dealings

Quality Investing

Details

7 / 10

Sales growth (10Y) > 5%

Revenue growth (3Y) > 5 %

EBIT growth (10Y) > 5%

EBIT growth (3Y) > 5 %

Net debt < 4x EBIT

Profitable since 10Y+

EBIT Drawdown (10Y) < 50%

Return on Equity (ROE) > 15%

ROCE > 15%

Return Expectation > 10%

PEG

1.48

P/E ratio

15.92

P/Ee 2026

21.42

P/Ee 2027

11.59

P/Ee 2028

10.71

P/Ee 2029

11.2

P/Ee 2030

11.65

P/S

4.47

P/Se

4.31

EV/EBIT

11.25

P/B Ratio

6.51

ROE (Return on Equity)

36.96 %

ROA (Return on Assets)

14.62 %

ROCE (Return on Capital Employed)

52.46 %

ROIC (Return on Invested Capital)

24.39 %

Gross Margin

81.5 %

EBIT Margin

41.19 %

Net Margin

28.08 %

EPS (Earnings Per Share)

7.28 USD

Net Debt / EBIT

—

Debt/Equity

0.8

Dividend

3.28 USD

Dividend yield

2.83 %

Est. Dividend Yield

0.73 %

Payout Ratio

55.59 %

Dividend growth Ø5Y

4.44 %

Dividend payments per year

Dividend paid since

36 years+

Dividend not reduced since

25 years

Dividend increased since

15 years

Dividend withholding tax

30 %

Last updated Mar 14, 2026, 3:12 PM

Merck & Co Presentations

Merck & Co Peer Group

Bristol-Myers Squibb Co

Pfizer Inc

Merck & Co Ticker

DÜSSELDORF · 6MK.DUFRANKFURT · 6MK.FHAMBURG · 6MK.HMLONDON · 0QAH.LMILAN · 1MRKX.MIMUNICH · 6MK.MUNEW YORK · MRKPARIS · MRK.PASIX · MRK1.SWVIENNA · MRK.VIXETRA · 6MK.DE

Merck & Co FIGI

MRK:US · BBG000BPD168MRK:UA · BBG000BPD1D0MRK:UC · BBG000BPD1P7MRK:UN · BBG000BPD257MRK:UP · BBG000BPD2C9MRK:UB · BBG000BPD2Y5MRK:UT · BBG000BPD3Q2MRK:UM · BBG000BPD408MRK:UX · BBG000BPD4Y1MRK:UD · BBG000BPD7Q3MRK:UF · BBG000BPDB66MRK:VY · BBG000BPDBK0MRK:VJ · BBG000BPDBW7MRK:VK · BBG000BPDDS86MK:GR · BBG000G57ZH76MK:GF · BBG000G580D76MK:GD · BBG000G582256MK:GY · BBG000G582T66MK:GS · BBG000G583J56MK:GM · BBG000G584P66MK:GB · BBG000G585K86MK:GI · BBG000G586N36MK:GH · BBG000G598P6MRK*:MM · BBG000HW8M21MRK*:MF · BBG000HW8MN8MRK:PE · BBG000KH3906MRK:EO · BBG000N7GF70MRK:XH · BBG000N7GGT4MRK:XC · BBG000N7GH67MRK:XF · BBG000N7GHJ3MRK:XE · BBG000N7GJX3MRK:XJ · BBG000N7GKL3MRK:XL · BBG000N7GLM0MRK:XG · BBG000N7GM48MRK:XO · BBG000N7GNL7MRK:XS · BBG000N7HSR9MRK:XA · BBG000N7HTH8MRK:E1 · BBG000N7HW63MRK:XT · BBG000N7HX07MRK:XW · BBG000N7JZL7MRK:EU · BBG000N7K176MRKGBX:EU · BBG000NGTDR9MRKGBX:EO · BBG000NGTFB1MRKGBX:XJ · BBG000NGVNY6MRKGBX:XL · BBG000NGWQV1MRKGBX:XG · BBG000NGWRJ3MRKGBX:E1 · BBG000NGWXK8MRKGBX:XT · BBG000NGWY53MRKGBX:XW · BBG000NGWYN3MRKEUR:EU · BBG000NH5C22MRKEUR:EO · BBG000NLC986MRKEUR:XE · BBG000NLDGF1MRKEUR:XL · BBG000NLDH50MRKEUR:XO · BBG000NLDJC8MRKEUR:E1 · BBG000NLDNC9MRKEUR:XT · BBG000NLDP34MRKEUR:XW · BBG000NLDPW2MRKCAD:EO · BBG000NT50Z6MRKCAD:E1 · BBG000NT6C52MRKCAD:XT · BBG000NT6CL4MRKCAD:XW · BBG000NT6D41MRKCAD:EU · BBG000NT6FQ2MRKJPY:EO · BBG000PB5QH6MRKJPY:E1 · BBG000PB74H3MRKJPY:XT · BBG000PB74N6MRKJPY:XW · BBG000PB75V4MRKJPY:EU · BBG000PB76Y94MRKX:TE · BBG000QFV217MRKN:TQ · BBG000RG49C76MK:TH · BBG000RYMRD7MRK:RO · BBG002YTKV67MRK:RE · BBG002YTKV76MRK:CI · BBG004BWL0B2MRK:CC · BBG004BWL0C1MRK:CE · BBG004BWL0D0MRK:XV · BBG00591DHG7MRKCAD:XV · BBG00591QH55MRKJPY:XV · BBG00591RXW9MRKN:B3 · BBG006T7V5V9MRKN:L3 · BBG006TC5S92MRK1:SW · BBG006TLRZF5MRK1:SE · BBG006TLRZH3MRK1:BW · BBG006TLRZM76MK:QT · BBG0077H4610MRKCHF:EO · BBG007F5XHG5MRKCHF:XH · BBG007F5XHL9MRKCHF:XF · BBG007F5XHN7MRKCHF:XE · BBG007F5XHQ4MRKCHF:XJ · BBG007F5XHR3MRKCHF:XL · BBG007F5XHS2MRKCHF:XG · BBG007F5XHT1MRKCHF:XO · BBG007F5XHV8MRKCHF:XS · BBG007F5XHZ4MRKCHF:XA · BBG007F5XJ08MRKCHF:E1 · BBG007F5XJ17MRKCHF:XT · BBG007F5XJ26MRKCHF:XW · BBG007F5XJ35MRKCHF:XU · BBG007F5XJ44MRKCHF:XV · BBG007F5XJ62MRKCHF:EU · BBG007F5XJ99MRKN:PO · BBG008H05F95MRKUSD:SW · BBG00DGYR2Y8MRKUSD:SE · BBG00DGYR303MRK:VF · BBG00DJCX9L56MK:GZ · BBG00FZMHTY0MRK:AV · BBG00GQ6S6Z00QAH:LN · BBG00JHW4ZD3MRK:XX · BBG00JN7B4G9MRKGBX:XX · BBG00JN7KLK6MRKEUR:XX · BBG00JN7L0K1MRKCAD:XX · BBG00JN7N458MRKJPY:XX · BBG00JN7PKZ7MRKCHF:XX · BBG00JN893T8MRK*:MU · BBG00JX0P1C8MRKRON:XS · BBG00PPYQ3K5MRKRON:XH · BBG00PPYQ3N2MRKRON:XF · BBG00PPYQ3Q9MRKRON:XD · BBG00PPYQ3R8MRKRON:XE · BBG00PPYQ3S7MRKRON:XJ · BBG00PPYQ3T6MRKRON:XL · BBG00PPYQ3V3MRKRON:XG · BBG00PPYQ3W2MRKRON:XO · BBG00PPYQ3X1MRKRON:XN · BBG00PPYQ3Y0MRKRON:XA · BBG00PPYQ414MRKRON:XT · BBG00PPYQ432MRKRON:XW · BBG00PPYQ441MRKRON:XU · BBG00PPYQ450MRKRON:XV · BBG00PPYQ469MRKRON:XM · BBG00PPYQ478MRKRON:EU · BBG00PPYQ4D1MRK:X2 · BBG00Q6R1GZ1MRKEUR:X2 · BBG00Q6R88P36MKD:PO · BBG00QKDHP896MKD:L3 · BBG00QKDJDN76MKD:B3 · BBG00QKDJV570QAHL:PO · BBG00VSGR5J40QAHL:L3 · BBG00VSGS4Z80QAHL:B3 · BBG00VSGSC17MRK:VP · BBG00X1PP3Z80QAHL:L1 · BBG00Y7B52T26MKD:L1 · BBG00Y7B7XH5MRKN:L1 · BBG00Y9254Z9MRKCL:CI · BBG00YFSTJJ4MRKCL:CC · BBG00YFSTJK2MRKCL:CE · BBG00YFSTJL1MRK-RM:RM · BBG00ZGWC634MRK-RM:RX · BBG00ZGWC643MRK-RM:RN · BBG00ZGWC652MRK-RM:RP · BBG00ZGWC661MRKRUB:XS · BBG00ZH8Q7B0MRKRUB:XH · BBG00ZH8Q7F6MRKRUB:XF · BBG00ZH8Q7H4MRKRUB:XE · BBG00ZH8Q7K0MRKRUB:XL · BBG00ZH8Q7M8MRKRUB:XG · BBG00ZH8Q7N7MRKRUB:XO · BBG00ZH8Q7P5MRKRUB:XA · BBG00ZH8Q7T1MRKRUB:XT · BBG00ZH8Q7W7MRKRUB:XW · BBG00ZH8Q7X6MRKRUB:XU · BBG00ZH8Q7Y5MRKRUB:XV · BBG00ZH8Q800MRKRUB:XM · BBG00ZH8Q819MRKRUB:EU · BBG00ZH8Q8G3MRK:UZ · BBG01496JKP5MRK:OU · BBG01496JKR3MRK:QU · BBG01496JKS26MK:LA · BBG018H7P3X76MK:LU · BBG018J1B6C96MKD:BQ · BBG018Z987Y26MK:BU · BBG01BBXFC796MKD:EB · BBG01FT5XQ996MKD:IX · BBG01FT5YNR56MKD:I2 · BBG01FT5Z9Z66MKD:S1 · BBG01FY4XXV66MKD:S4 · BBG01FY4XY806MKD:QX · BBG01K0W2QC06MKD:QE · BBG01K0W2S181MRKX:IM · BBG01K3YB9H61MRKX:IF · BBG01K3YB9K2

All fundamentals about Merck & Co

Our stock analysis for Merck & Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Merck & Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Merck & Co Revenue→

Merck & Co Net Income→

Merck & Co Directors Dealings→

Merck & Co Stocks→

Merck & Co Market capitalization→

Merck & Co Debt→

Merck & Co Liabilities→

Merck & Co Equity→